Robert N. Osdyke, Inc Podiatrist - Foot & Ankle Surgery Medicare: Not Enrolled in Medicare Practice Location: 15421 Clayton Rd, Suite G1, Ballwin, MO 63011 Phone: 636-207-0444 Fax: 636-207-0446 |
Mo Foot & Ankle Podiatrist - Foot & Ankle Surgery Medicare: Not Enrolled in Medicare Practice Location: 15945 Clayton Rd, Ballwin, MO 63011 Phone: 636-256-5298 |
F & A Center Clarkson Valley Podiatrist - Foot & Ankle Surgery Medicare: Not Enrolled in Medicare Practice Location: 15945 Clayton Rd, Suite 220, Ballwin, MO 63011 Phone: 314-487-9300 |
Dr. Tiffany Monique Delutis, DPM Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 1393 Big Bend Rd Ste A, Ballwin, MO 63021 Phone: 636-496-0022 Fax: 636-825-9756 |
News Archive
Alexion Pharmaceuticals, Inc. today announced that the European Commission (EC) has extended the therapeutic indication for Soliris® (eculizumab) to include the treatment of pediatric and adult patients with atypical hemolytic uremic syndrome (aHUS).
Veterans exposed to herbicides while serving in Vietnam and other areas will have an easier path to access quality health care and qualify for disability compensation under a final regulation that will be published on August 31, 2010 in the Federal Register by the Department of Veterans Affairs (VA). The new rule expands the list of health problems VA will presume to be related to Agent Orange and other herbicide exposures to add two new conditions and expand one existing category of conditions.
An innovative robotic sample management system developed by the SME-led PMS project carries out complex sample transport operations rapidly and with a high level of reliability. It includes a new transport system based on magnetic hover railway technologies, a new laboratory information system and a special selective analyser. PMS partners are now predicting a substantial market share for their transport system.
OriGene Technologies, Inc., a leading gene-centric life sciences company, announced the completion of a $16 million Series B financing led by IDG-Accel, SBI & TH Venture Capital Enterprise, and Zero2IPO. OriGene's previous investors Morningside Venture Investments and President International Development Corp. (PIDC) also participated in this round. The proceeds from the funding will be used to continue to build OriGene's TrueMAB™ monoclonal antibody collection.
The results of a study presented today at the Annual European Congress of Rheumatology (EULAR 2018) demonstrate that canakinumab significantly reduced the rate of gout by more than half compared to placebo, regardless of baseline serum urate level.
› Verified 5 days ago